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oninvasive Diagnosis of
iopsy-Proven Cardiac Amyloidosis
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ichard E. Thompson, PHD,‡ Chih Kuo, MD,† E. Rene Rodriguez, MD,† Joshua M. Hare, MD,*
enneth L. Baughman, MD, FACC,* Edward K. Kasper, MD, FACC*
altimore, Maryland
OBJECTIVES This study analyzed the utility of electrocardiographic (ECG) and echocardiographic findings
in the diagnosis of amyloidosis proven by endomyocardial biopsy.
BACKGROUND Cardiac amyloidosis is associated with characteristic ECG and echocardiographic changes,
yet each finding alone is relatively nonspecific. A combination of noninvasive prognostic
parameters would be desirable for this tissue-based diagnosis.
METHODS We performed an analysis of 196 consecutive patients referred for endomyocardial biopsy
because of clinical suspicion of cardiac amyloidosis. The diagnosis was confirmed in 58
patients (29%). The ECGs, echocardiograms, and right heart hemodynamic data were
reviewed to determine which findings strongly correlate with the diagnosis. These findings
were then used to build multivariate logistic regression models that predict the log-odds of
having cardiac amyloidosis.
RESULTS The univariate analysis showed that low-voltage and pseudo-infarction patterns on the ECG
and increased myocardial thickness and speckled-appearing myocardium on the echocardio-
gram were associated with biopsy-proven cardiac amyloidosis (each p  0.01). In multivariate
logistic regression models, a combination of a low voltage and measures of myocardial
thickness produced the most statistically useful models. For instance, one model showed that
if a low voltage was present and interventricular septal thickness is 1.98 cm, the diagnosis
of cardiac amyloidosis could be made with a sensitivity of 72% and a specificity of 91%. In this
model, the positive predictive and negative predictive values were 79% and 88%, respectively.
CONCLUSIONS In patients with suspected cardiac amyloidosis, a combination of noninvasive parameters—
namely, a low voltage and increased intraventricular septal thickness—is a useful diagnostic
tool. (J Am Coll Cardiol 2004;43:410–5) © 2004 by the American College of Cardiology
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dmyloidosis frequently involves the heart. Deposition of
myloid fibrils in myocardial tissue results in reduced
entricular compliance with impairment of relaxation and
ventually contraction. Amyloid fibrils may also deposit in
yocardial vessels and cause local ischemia. Amyloid dep-
sition is associated with fibrosis of conduction tissue,
esulting in conduction abnormalities and arrhythmias.
alvular dysfunction from amyloid deposition may also
ccur. Cardiac amyloidosis is associated with a variable but
enerally poor prognosis (1), and early recognition may
mprove the outcome.
The diagnosis of cardiac amyloidosis can be difficult
ecause the clinical presentation is similar to that of other
ardiomyopathies. Cardiac amyloidosis is suggested by
haracteristic echocardiographic findings—namely, a gran-
lar myocardial appearance, thickened ventricular walls,
trial dilation, and diastolic dysfunction progressing to
From the *Division of Cardiology, Department of Medicine, and †Department of
athology, Johns Hopkins University School of Medicine; and ‡Department of
iostatistics, Johns Hopkins School of Public Health and Hygiene, Baltimore,
aryland. This study was funded by the Charity Mae Foundation, Fargo, North
akota.
Manuscript received April 30, 2003; revised manuscript received August 21, 2003,tccepted August 25, 2003.ystolic dysfunction (2). The ECG frequently demonstrates
ow-voltage and pseudo-infarct patterns, conduction abnor-
alities, and arrhythmias. However, each finding alone is
onspecific. In this study, we aimed to determine which
arameters or combination of parameters correlate with
ndomyocardial biopsy-proven cardiac amyloidosis and thus
an be used to predict disease status.
ETHODS
tudy patients. This is a retrospective case-control study of
96 patients who were referred to the Johns Hopkins
edical Institutions between January 1984 and May 2000
or endomyocardial biopsy because of a clinical suspicion of
ardiac amyloidosis. Patients were referred for evaluation of
ongestive heart failure (CHF) in the setting of established
ystemic amyloidosis, multiple myeloma, connective tissue
isease, and chronic inflammatory disorders, or clinical
eatures suggestive of these systemic disorders. There were
o other specific criteria for inclusion or exclusion. Approval
or this study was obtained from the Johns Hopkins
edicine Institutional Review Board. We performed a
etailed examination of the medical records of these pa-
ients. In addition, we obtained approval to conduct phone
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February 4, 2004:410–5 Noninvasive Diagnosis of Cardiac Amyloidosisalls to patients or their surviving family members to
etermine accurate mortality information. Informed con-
ent was obtained during the phone conversations. Seventy-
wo percent of patients or their surviving family members
ere reached by phone. The National Death Registry was
sed to confirm the status of the remainder.
A review of the medical records was performed by a team
f physicians blinded to the endomyocardial biopsy results.
iopsy results were separated from other patient informa-
ion and introduced into the data base after collection of
linical data was completed. The following information was
eviewed and recorded: demographic data, New York Heart
ssociation (NYHA) heart failure class at the time of
iopsy, ECG findings, echocardiographic results, and he-
odynamic parameters derived from right heart catheter-
zation performed at the time of biopsy.
The ECGs were analyzed for the following characteris-
ics: rhythm, conduction abnormalities (i.e., right or left
undle branch block), a low-voltage pattern (defined by
otal height of the QRS complex in the limb leads 5 mm
nd 10 mm in the precordial leads), a pseudo-infarction
attern (pathologic Q waves on the ECG, but no coronary
rtery disease by angiography), and a left or right atrial
bnormality. The echocardiograms were analyzed for the
ollowing characteristics: interventricular septal (IVS) thick-
ess, posterior wall thickness, left ventricular (LV) diastolic
iameter, LV systolic diameter, atrial size, pericardial effu-
ion size (if present), overall ejection fraction, and granular/
parking appearance of the myocardium by visual inspec-
ion. Standard hemodynamic data obtained from right heart
atheterizations were reviewed.
ndomyocardial biopsy. The endomyocardial biopsies
ere obtained in the standard fashion. A minimum of four
iopsies were taken from each patient. All biopsies were
xamined by a single, experienced pathologist who was
linded to all other study data. The biopsies were analyzed
ith a standard hematoxylin-eosin preparation. All biopsies
ere also stained with congo red to identify the presence of
myloidosis. If the congo red staining was equivocal, the
iopsy was reviewed under electron microscopy to confirm
he diagnosis. Finally, all biopsies with amyloidosis under-
ent immunohistochemical staining to help ascertain the
xact etiology of the amyloid. Staining was performed for
myloid AL and transthyretin. They were also stained for
hioflavin T, a more sensitive stain for amyloidosis (com-
Abbreviations and Acronyms
CHF  congestive heart failure
ECG  electrocardiogram/electrocardiographic
IVS  interventricular septal
LV  left ventricular
NYHA  New York Heart Association
OR  odds ratioared with congo red staining), but not specific for the mource of the amyloid. Stains for lambda and kappa light
hains were available in a limited number of the patients.
tatistical analysis. All statistical analyses were performed
sing the statistical software package STATA version 7.0.
s an initial step, univariate analyses were performed on all
emographic and cardiac variables of interest to determine
hich set of variables was statistically associated with
ardiac amyloidosis. Continuous variables were assessed
sing the parametric t test for independent samples (e.g.,
ean arterial pressure, right ventricular systolic pressure),
nd all categorical variables were assessed using the chi-
quare goodness-of-fit test (e.g., square root sign). Those
ariables that were found to be associated with disease status
ere then used to build multivariate logistic regression
odels that predict the log-odds of being positive for
myloidosis on endomyocardial biopsy. We first considered
odels with only noninvasive cardiac variables and then
dded invasive measures to see whether these variables
ould increase our ability to predict disease status.
ESULTS
iopsy and survival results. A total of 196 patients were
valuated. Fifty-eight of these patients (29.1%) had an
ndomyocardial biopsy diagnostic of cardiac amyloid. Eight
f these patients also had lymphocytic infiltrates, which met
he Dallas criteria for myocarditis. Of the remaining 138
atients (70.9%), the most common diagnosis was hyper-
rophy with evidence of interstitial fibrosis (which occurred
n 66 patients). Thirty-five patients had hypertrophy with-
ut interstitial fibrosis, and 22 patients had myocarditis
Table 1).
The mean post-biopsy survival varied with the biopsy
esult. For all 58 patients with amyloidosis, the mean
urvival duration was significantly shorter than that of the
est of the patients (364 vs. 1,053 days, p  0.001).
oreover, the subset of eight amyloidosis patients who had
vidence of myocardial inflammation had an even poorer
urvival (66 days, p  0.001). All other patients with
iagnoses had a survival duration of 1,000 days, except for
atients with interstitial fibrosis or an indeterminate biopsy.
atient characteristics. The demographic, clinical, and
emodynamic characteristics of the patients, according to
heir biopsy results, are shown in Tables 2 and 3. Patients in
he amyloidosis group were slightly older and more often
able 1. Summary of Biopsy and Survival Results
Biopsy Results
Patients
(n  196)
Mean Duration of
Survival After Biopsy
(days)
myloidosis 50 412
myloidosis and myocarditis 8 66
yocyte hypertrophy with/
without interstitial fibrosis
66/35 1,114
yocarditis 22 1,025
onspecific findings 15 727ale. The duration of symptoms before obtaining the
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Noninvasive Diagnosis of Cardiac Amyloidosis February 4, 2004:410–5iopsy was no different between the groups. However, the
myloidosis group had a larger percentage of patients with
ore advanced heart failure (i.e., NYHA class III/IV). The
emodynamic data are also consistent with a greater degree
f hemodynamic compromise in the amyloidosis group.
lectrocardiography. Table 4 summarizes the ECG find-
ngs. Both low-voltage and pseudo-infarction patterns were
tatistically more prevalent in the patients with cardiac
myloidosis. Left bundle branch block was found to be less
revalent in the amyloidosis group (4% vs. 14%), but this
id not quite achieve statistical significance (p  0.065).
chocardiography. Table 5 summarizes the echocardio-
raphic findings. The mean IVS thickness and posterior
able 2. Summary of Demographic and Background
edical Data
Amyloid
Group
(n  58)
Negative
Biopsy
Group
(n  138) p Value
ean age (yrs) 64.0 59.8 0.058
ender (%)
Male 72% 57% 0.002
Female 28% 43%
ace (%)
Caucasian 69% 70% NS
African American 31% 25% NS
HF class at presentation  0.001
I — —
II 19% 37%
III 47% 43%
IV 33% 20%
ean duration of symptoms
(months)
15.4 16.2 NS
levated creatinine (% of
patients with 2 mg/dl)
21% 11% 0.002
hrombocytopenia (% of
patients with 150 K)
23% 18% NS
HF  congestive heart failure; NS  not significant.
able 3. Clinical and Hemodynamic Characteristics According
o Biopsy Result
Amyloid
Group
(n  58)
Negative
Biopsy Group
(n  138) p Value
R (beats/min) 81 80 NS
AP (mm Hg) 87 95 0.0030
VSP (mm Hg) 46 44 NS
VDP (mm Hg) 12 12 NS
PAP (mm Hg) 30 28 0.1100
CWP (mm Hg) 21 18 0.0193
I (l/min per m2) 1.70 2.18  0.0001
V (ml) 43.3 54.2 0.0002
VRI (dynes·s·m2/cm5) 3,888.7 3,224.5 0.0145
VSWI (g/m per m2) 20.1 29.2 0.0001
quare root sign (%) 0 4 0.112
qualization of diastolic
pressure (%)
2 11 0.036
I  cardiac index; HR  heart rate; LVSWI  left ventricular stroke work index;
AP  mean arterial pressure; MPAP  mean pulmonary artery pressure; NS 
onsignificant; PCWP  pulmonary capillary wedge pressure; RVDP and RVSP 
ight ventricular diastolic and systolic pressure, respectively; SV  stroke volume;dVRI  systemic vascular resistance index.all thickness were significantly larger in patients with
myloidosis (1.6 vs. 1.2 cm, p  0.0001). Also, the LV
ystolic and diastolic diameters were both significantly
maller in patients with amyloidosis. Patients with amyloid-
sis were also more likely to have restrictive physiology
increased E wave and decreased A wave) and a sparkling/
ranular appearance to the myocardium.
mmunohistochemical staining. Immunohistochemical
taining with congo red was performed on all patients to
scertain the etiology of amyloidosis (Table 6). There were
even patients who stained positive for amyloid AL, sug-
esting that light-chain deposition from multiple myeloma
as the etiology of their amyloidosis. Seven patients stained
ositive for transthyretin amyloidosis. Two patients stained
ositive for both amyloid AL and transthyretin. No other
pecific immunohistochemical stains were performed (e.g.,
or amyloid AA). However, staining for thioflavin T (a
ore specific marker for amyloidosis than congo red) was
erformed. A total of 34 patients (including the 13 patients
ith amyloid AL and transthyretin) stained positive. There-
ore, 24 patients were congo red–positive but did not have
ny positive immunohistochemical stains.
ogistic regression models. Table 7 summarizes the lo-
istic regression models for the probability of biopsy-proven
myloidosis, using the independent variables of IVS thick-
ess, low voltage, patient age, gender, and race (white vs.
onwhite). With respect to the odds ratios (OR), the
ategorical variable base levels are female, white, and the
bsence of a low voltage on the ECG. For the continuous
ariables of IVS thickness and age, the ORs are given for
ach unit increase in the variable. Thus, in model 1, the OR
f amyloidosis is 1.97 times greater for males than for
emales, 1.75 times greater for whites than nonwhites, and
.38 times greater for patients with a low voltage than a
ormal voltage. In addition, each year increase in age gives
n OR of 1.02 for a positive result, and each unit increase in
VS thickness produces a 7.7-fold increased risk of having
ardiac amyloidosis. However, the ORs are statistically
able 4. Electrocardiographic Findings
Amyloid
Group
(n  48)
Negative
Biopsy
(n  128)
Chi-Square
Result
trial flutter 0% 3% 0.215
trial fibrillation 19% 30% 0.322
eft atrial abnormality 15% 20% 0.386
ight atrial abnormality 0% 4% 0.165
irst-degree AV block 13% 5% 0.112
nterventricular conduction
delay
8% 10% 0.960
BBB 4% 14% 0.065
BBB 17% 12% 0.386
aced rhythm 8% 20% 0.075
ow voltage 56% 13%  0.001
seudo-infarction 60% 36%  0.001
V  atrioventricular; LBBB and RBBB  left and right bundle branch block;
espectively.ifferent from 1.0 for IVS thickness and low voltage only.
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February 4, 2004:410–5 Noninvasive Diagnosis of Cardiac AmyloidosisTherefore, a more parsimonious model (model 2) that
ncludes only IVS thickness and low voltage may be con-
idered. In this model, the OR of cardiac amyloidosis is 7.34
imes greater for patients with a low voltage than a normal
oltage, and for every 1-cm increase in IVS thickness, there
s 10.4-fold higher likelihood of a positive biopsy.
This model can also be used to formulate a simple yet
owerful test for the likelihood of amyloidosis. By utilizing
he mathematic equations that define this model, one is able
o define a cut-off point for IVS thickness, which can serve
s a testing parameter (Appendix). We have demonstrated
hat for patients with a low voltage, a cut-off point of 1.98
m for IVS thickness optimizes both the sensitivity and
pecificity of our model to predict the presence of amyloid-
sis. Similarly, a cut-off point of 1.13 cm for IVS thickness
an be defined as the testing point that maximizes the
ensitivity and specificity of the test for patients without a
ow voltage. Thus, in our test, a patient with an ECG that
hows a low voltage and an echocardiogram with an IVS
hickness of 1.98 cm will be classified as having amyloid-
sis. Likewise, a patient with a low voltage but IVS
hickness 1.98 cm would be classified as not having
myloidosis. Our test yields a positive predictive value of
9% and a negative predictive value of 88%. Table 8 shows
he sensitivity, specificity, and positive and negative predic-
ive values of our test.
ISCUSSION
he diagnosis of cardiac amyloidosis is important for
rognosis and therapy. The clinical presentation varies and
Table 5. Echocardiographic Findings
LV diastolic diameter (cm)
LV systolic diameter (cm)
Left atrial size (cm)
IVS thickness (cm)
Posterior wall thickness (cm)
Restrictive physiology (increased E/A)
Sparkling/granular appearance of myocardium
Biatrial enlargement
E/A reversal
Wall motion abnormality
LV ejection fraction
Data are presented as the mean value or number (%) of pati
E/A  ratio of early transmitral flow velocity to atrial flo
able 6. Immunohistochemical Staining Results
Stain
Number of
Patients
myloid AL 7
ransthyretin (TTR) 4
myloid AA and TTR 2
hioflavin T 21
ongo red only 24 may mimic other infiltrative cardiomyopathies or storage
isorders, as well as hypertrophic cardiomyopathy. Previous
nvestigations have shown that multiple ECG and echocar-
iographic findings suggest amyloid but are nonspecific in
solation. Typically, there is echocardiographic evidence of
hickened ventricular and septal walls, a normal or small
entricular size, atrial enlargement, and refractile myocar-
ium (3), as well as a low voltage on the ECG. The finding
f increased myocardial echogenicity is 87% sensitive and
1% specific for cardiac amyloid when compared with
ontrol subjects with LV hypertrophy (4). The use of a
ombination of echocardiographic and ECG features in-
reases specificity. In the same study, increased echogenicity
lus increased atrial septal thickness is 67% sensitive and
00% specific for cardiac amyloid. However, prospective
dentification of refractile echocardiograms is not precise
ue to observer dependence and technical manipulations
uring imaging (1). A distinctive characteristic of amyloid
ardiomyopathy is the inverse relationship between ECG
oltage and LV mass (5). A low voltage on the ECG and
ncreased septal and posterior LV wall thickness on the
chocardiogram are highly specific for cardiac amyloidosis
n the setting of biopsy-proven systemic amyloidosis (6). To
he best of our knowledge, the diagnostic parameters of the
forementioned echocardiographic and ECG features have
ot been determined in a cohort of patients with endomyo-
ardial biopsy-proven amyloidosis. In this study, we aimed
o establish the sensitivity and specificity of the typical
chocardiographic and ECG features of cardiac amyloid-
sis, as well as a model derived from noninvasive parameters
hat is predictive of disease status.
Logistic regression models that predict the log-odds of
ardiac amyloidosis were developed, based on noninvasive
arameters. Multiple models were used to determine the
iagnostic parameters of sensitivity, specificity, and predic-
ive value. Models using myocardial echogenicity paired
ith wall thickness or low voltage were highly predictive of
ardiac amyloidosis, but not more so than the selected
loid Group
n  47)
Negative Biopsy
Group
(n  115) p Value
4.2 5.2  0.0001
3.1 3.7 0.0200
4.6 4.5 0.7656
1.6 1.2  0.0001
1.6 1.2  0.0001
4 (30%) 13 (11%) 0.004
2 (26%) 5 (4%)  0.001
3 (28%) 44 (38%) 0.200
7 (15%) 26 (23%) 0.269
8 (17%) 25 (22%) 0.499
44% 42% 0.7030
city; IVS  interventricular septal; LV  left ventricular.Amy
(
1
1
1
ents.odel utilizing septal thickness and low voltage. Use of
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Noninvasive Diagnosis of Cardiac Amyloidosis February 4, 2004:410–5hese variables is simpler and lessens the variability associ-
ted with identifying granular myocardium. We propose
hat in patients with clinical suspicion of cardiac amyloid,
he combination of septal thickness and low voltage can be
sed for diagnosis. Additionally, serial echocardiography
an be used to follow the patient’s clinical status and
esponse to treatment. Others have demonstrated that
ncreasing LV wall thickness and mass/voltage ratio are
ssociated with shorter survival (7).
tudy limitations. This study has several limitations. Pa-
ients were referred for suspicion of cardiac amyloidosis and
herefore likely had an increased incidence of ECG and
chocardiographic evidence of myocardial involvement.
owever, this would lessen any observed difference between
he groups. A chart review did not provide sufficient
nformation to determine the NYHA heart failure class at
he time of echocardiography and endomyocardial biopsy. It
as been demonstrated that clinical CHF strongly correlates
ith the degree of echocardiographic abnormalities, in
articular, increased wall thickness (7). In this study, a
igher incidence of clinical CHF in those with histologic
vidence of cardiac amyloid would falsely create or amplify
difference in echocardiographic abnormalities between
roups. However, it has been demonstrated that ECG and
chocardiographic changes consistent with amyloid are
etectable before the development of CHF (8).
Another confounding factor may be the combined anal-
sis using primary and secondary amyloidosis. It is known
hat the type and amount of cardiac dysfunction is related to
he type and extent of amyloid infiltration. At autopsy, it has
een demonstrated that septal thickness is higher in primary
Table 7. Summary of Logistic Regression Mod
Variable
Model 1
OR (CI)
Age 1.024 (0.983–1.065)
Gender 1.973 (0.631–6.166)
Race 1.754 (0.597–5.150)
IVS thickness 7.689 (2.245–26.335)
Low voltage 8.382 (2.865–24.525)
n 115
Deviance 98.899
H-L p value 0.7827
In addition to presenting the odds ratios (OR) and correspo
table also gives the total number of patients included in the mo
(H-L) goodness-of-fit test, and the area under the curve obta
of the regression model is a measure of the model’s fidelity t
fidelity (e.g., low deviance) but that are also parsimonious (e.g
H-L test is a goodness-of-fit test that compares the model’s p
the data, so a nonsignificant p value for this test suggests th
IVS  interventricular septal.
able 8. Predictive Ability of Model 2
ensitivity 72.22%
pecificity 91.25%
ositive predictive value 78.79%
egative predictive value 87.95%nd familial amyloidosis than in secondary amyloidosis (9).
tudies comparing echocardiographic findings between
ypes of amyloidosis have yielded conflicting results. One
tudy demonstrated an increased IVS thickness in primary
myloidosis compared with familial and secondary amyloid-
sis (10), but another study did not show any significant
ifference in septal thickness between primary and familial
myloidosis (11). It is also known that amyloid AA rarely
nvolves the heart (12), so the potential effect on interpre-
ation of this data is unclear.
Cardiac amyloidosis is associated with a variable progno-
is. In primary amyloidosis, the median survival is six
onths once heart failure develops. For senile amyloidosis,
he median survival is five years once heart failure de-
elops (13). Because of therapeutic and prognostic implica-
ions, it is important that a tissue diagnosis is made. We
ropose that if a histopathologic diagnosis is available
rom other tissue, that the findings of increased septal
hickness and low voltage are sufficient for the diagnosis
f cardiac amyloidosis, as the specificity is high for patients
ith suspected cardiac involvement. Recent research from
ispenzieri et al. (14) suggests that elevated cardiac tro-
onins may also be useful in the detection and prognosis
f cardiac amyloidosis in patients with known systemic
myloidosis.
ecommendations for further study. It is noted that this
tudy identified a subset of patients having evidence of
oth amyloidosis and myocarditis. This histopathologic
nding was strikingly associated with a worse prognosis. To
he best of our knowledge, this has not been previously
eported. In this subset of patients, the ECG and echocar-
iographic findings were not significantly different from
hose with other forms of amyloidosis. This finding would
avor the use of endomyocardial biopsy over noninvasive
easures in the diagnosis of cardiac amyloid, as this
istologic finding has important prognostic implications.
e recommend further study to define this pathologic
ntity and its clinical features.
Model 2
ue OR (CI) p Value
57
43
07
01 10.389 (2.986–36.141)  0.001
01 7.337 (2.682–20.070)  0.001
116
103.955
0.4392
confidence interval (CI) for each independent variable, this
e model deviance, the p values from the Hosmer-Lemeshow
rom receiver-operating characteristics analysis. The deviance
ata. Ideally, we would like to seek models that have a high
as few a number of independent variables as possible). The
ions with the data. The null hypothesis is that the model fits
cannot reject this hypothesis.els
p Val
0.2
0.2
0.3
0.0
 0.0
nding
del, th
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PPENDIX
ased on the following logit coefficients for model 2:
logit   4.631  1.993*X  2.341*IVS
here X  0 if low voltage is “false” and 1 if “true,” and the
elationship between the probability of a positive response
nd the logistic coefficients:
probcardiac amyloidosis

exp  4.631  1.993*X  2.341*IVS
1  exp  4.631  1.993*X  2.341*IVS
e can solve for the values of IVS thickness and low voltage
hat give the cut-off probability of 0.5.
For patients with a low voltage, the cut-off value of IVS
hickness is equal to 1.98 cm, and the cut-off value of IVS
hickness for a normal voltage is equal to 1.13 cm.
